Medtronic Receives FDA Marketing Clearance For Complete SE Biliary Stent System

SANTA ROSA, Calif.--(HSMN NewsFeed)--Medtronic, Inc. (NYSE:MDT ), announced today that it has received 510(k) marketing clearance from the U.S. Food and Drug Administration for the Complete SE (self-expanding) Biliary Stent System, which is indicated for use in the palliative treatment of malignant neoplasms in the biliary tree – cancerous tumors in the bile duct that can compromise digestion by restricting the flow of digestive fluids.

U.S. commercial sales of the new biliary stent will begin immediately in a wide size range, with diameters of 4 – 10 mm and lengths of 20 – 150 mm.

Full text >>